The single-inhaler demonstrated a meaningful improvement in lung function in the Phase III KALOS and LOGOS studies.

AstraZeneca has announced the Positive high-level results from the Phase III KALOS and LOGOS trials in patients with ...

AstraZeneca’s fixed-dose triple-combination therapy, Breztri meets primary endpoints in KALOS & LOGOS phase III trials in asthma: Cambridge, UK Saturday, May 3, 2025, 10:00 Hrs ...

AstraZeneca (LSE:AZN) recently announced phase III trial results for Breztri Aerosphere, its triple-combination asthma ...

The replicate confirmatory KALOS and LOGOS trials evaluated BGF in participants with severe asthma inadequately controlled with standard of care.

The FDA pushed back its decision date on Cytokinetics’ heart drug. Elsewhere, Repare Therapeutics licensed its drug discovery ...

AstraZeneca has taken a key step in advancing Breztri Aerosphere toward a potential label expansion and achieving its goal of ...

Kura gets $45M from Kyowa Kirin; Pliant cuts 45% staff; AstraZeneca's Breztri succeeds in asthma trials; Otsuka ends ...

Anglo-Swedish pharma major AstraZeneca has presented positive top-line results from the Phase III KALOS and LOGOS trials in ...

Positive results from the Phase III KALOS and LOGOS trials show that AstraZeneca's Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumar ...

AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma.

Polestar (PSNY) is recalling 27,816 vehicles in the U.S., citing issues with rear camera image display, U.S. auto safety ...